Teleflex Incorporated (NYSE:TFX) Receives Average Recommendation of “Hold” from Analysts

Shares of Teleflex Incorporated (NYSE:TFX) have been given an average recommendation of “Hold” by the eleven ratings firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and two have given a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $169.63.

Several research analysts have weighed in on TFX shares. StockNews.com lowered Teleflex from a “buy” rating to a “hold” rating in a report on Friday, February 28th. Wells Fargo & Company reduced their target price on Teleflex from $214.00 to $146.00 and set an “equal weight” rating on the stock in a report on Friday, February 28th. Bank of America lowered Teleflex from a “neutral” rating to an “underperform” rating and reduced their target price for the stock from $235.00 to $140.00 in a report on Tuesday, March 4th. Mizuho set a $155.00 target price on Teleflex in a report on Wednesday, April 16th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Teleflex in a report on Wednesday, March 12th.

Hedge Funds Weigh In On Teleflex

Hedge funds have recently made changes to their positions in the business. Vontobel Holding Ltd. grew its stake in shares of Teleflex by 21.9% during the 4th quarter. Vontobel Holding Ltd. now owns 1,393 shares of the medical technology company’s stock worth $248,000 after acquiring an additional 250 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Teleflex by 14.3% in the third quarter. JPMorgan Chase & Co. now owns 155,158 shares of the medical technology company’s stock valued at $38,374,000 after buying an additional 19,466 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Teleflex by 5.2% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 108,231 shares of the medical technology company’s stock valued at $19,263,000 after buying an additional 5,322 shares in the last quarter. Lecap Asset Management Ltd. bought a new position in shares of Teleflex in the fourth quarter valued at $729,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Teleflex by 35.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,875 shares of the medical technology company’s stock valued at $1,053,000 after buying an additional 1,527 shares in the last quarter. 95.62% of the stock is owned by institutional investors.

Teleflex Stock Down 0.4 %

Shares of Teleflex stock opened at $134.69 on Tuesday. The company has a quick ratio of 1.39, a current ratio of 2.42 and a debt-to-equity ratio of 0.37. Teleflex has a 12 month low of $124.66 and a 12 month high of $249.91. The business has a fifty day simple moving average of $139.36 and a 200 day simple moving average of $172.78. The stock has a market cap of $6.25 billion, a PE ratio of 26.78, a price-to-earnings-growth ratio of 1.73 and a beta of 1.19.

Teleflex (NYSE:TFX) last announced its quarterly earnings data on Thursday, February 27th. The medical technology company reported $3.89 EPS for the quarter, topping analysts’ consensus estimates of $3.86 by $0.03. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. The business had revenue of $795.40 million during the quarter, compared to analysts’ expectations of $813.24 million. Research analysts predict that Teleflex will post 13.98 EPS for the current year.

Teleflex Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, March 17th. Stockholders of record on Friday, March 7th were paid a dividend of $0.34 per share. The ex-dividend date was Friday, March 7th. This represents a $1.36 annualized dividend and a dividend yield of 1.01%. Teleflex’s dividend payout ratio is currently 95.77%.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.